Navigation Links
The reason why antiviral therapy can't annihilate HIV infection, and what to do about it

Antiviral therapy has been used to suppress HIV replication and has dramatically improved the clinical course of disease in affected patients. But the existence of viral reservoirs precludes the complete elimination of HIV from treated patients. In a new study appearing on November 1 in The Journal of Clinical Investigation, Tae-Wook Chun and colleagues from the NIH offer new insight into the eradication of HIV in infected individuals receiving antiviral therapy.

The authors focused on HIV-infected patients who had received effective antiviral therapy for extended periods of time and examined the nature of their residual virus as well as the underlying mechanisms of viral persistence. They demonstrate that HIV persists in both resting and activated CD4+ T cells of patients having received up to 9.1 years of effective antiviral therapy with undetectable levels of HIV in their plasma.

Their data also suggest that latently infected, resting CD4+ T cells may become reactivated, most likely as a result of normal immunologic responses to various antigens and cytokines. In turn, virions released during the reactivation process may spread to neighboring resting as well as activated CD4+ T cells; direct cell-to-cell spread in the absence of virion release may also occur.

The study could impact the design of future therapies aimed at eradicating HIV in patients who have received effective antiviral therapy for extended periods of time. Considering that reactivation of latently infected, resting CD4+ T cells contributes to the persistence of HIV and initiation of new infection cycles, co-administration of an effective and safe reagent that is capable of dampening cellular activation could minimize the spread of virions to uninfected bystander cells.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Bobbing birds do it for a reason
2. A reason why video games are hard to give up
3. Leading reason for corneal transplants comes into focus
4. Novel antiviral technology inhibits RSV infection in mice
5. Biota makes major antiviral discovery
6. New possibilities for flu antiviral and vaccine research emerge from Spanish flu virus
7. Bird flu -- Call for antiviral drugs to be shared
8. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
9. Columbia research lifts major hurdle to gene therapy for cancer
10. Combination therapy boosts effectiveness of telomere-directed cancer cell death
11. Gene therapy converts dead bone graft to new, living tissue
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the ... research that could lead to one good one. Surviving Mesothelioma has just posted an ... The team evaluated 98 mesothelioma patients who got a second kind of ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
(Date:5/24/2016)... Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... financial planning for corporate executives and entrepreneurs, held The Future of San Diego Life ... in the San Diego life science community attended the event with speakers Dr. Rich ...
(Date:5/23/2016)... ... 23, 2016 , ... PrecisionAg® Media has released its latest ... The paper outlines the key trends that are creating both opportunities and challenges ... lot of highs and lows as the precision agriculture market has grown and ...
Breaking Biology Technology: